The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...

fuelled by robust pipeline progress and the US Food and Drug Administration (FDA) approval of its antipsychotic drug Cobenfy for the treatment of schizophrenia in September 2024. Cobenfy is ...

However, this came as good news for investors in AbbVie’s peer Bristol Myers Squibb (NYSE:BMY) as the company recently secured the U.S. FDA approval for its schizophrenia drug Cobenfy ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Lastly, we are pleased with the progress of our portfolio as Voranigo and Cobenfy were recently approved by the FDA. Based on our robust deal pipeline, our leading position as the partner of ...

We're also delighted to see our portfolio progress nicely with the FDA approvals of Cobenfy in schizophrenia and Voranigo in glioma and Tremfya in ulcerative colitis. We expect each of these to be ...

GlobalData analyst Alison Labya credited BMS’ surge to its “robust pipeline progress” and the FDA approval of schizophrenia drug Cobenfy. Meanwhile, Gilead rode the approval of primary ...

Lastly, we are pleased with the progress of our portfolio as Voranigo and Cobenfy were recently approved by the FDA. Based on our robust deal pipeline, our leading position as the partner of choice in ...